The company has developed a patented DNA-based technology platform called GA-map® that generates profiles of a patient’s gut microbiota and can be related to various health conditions. Its first product, the GA-map® Dysbiosis Test, is a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. The test is commercially available, standardized, and clinically validated. The company is actively involved in developing further clinical applications for the tests in areas such as diagnosis, disease severity course, treatment prediction, and monitoring within both IBS and IBD. Genetic Analysis AS also has an interest in metabolic disease, including diabetes type 2.